---
title: "Intensity Therapeutics, Inc. (INTS.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/INTS.US.md"
symbol: "INTS.US"
name: "Intensity Therapeutics, Inc."
industry: "Biotechnology"
---

# Intensity Therapeutics, Inc. (INTS.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.intensitytherapeutics.com](https://www.intensitytherapeutics.com) |

## Company Profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sa...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.21 | 211/605 | - | - | - |
| PB | 1.96 | 177/605 | 17.63 | 6.35 | 3.38 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-01T05:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 4 | 80% |
| Overweight | 0 | 0% |
| Hold | 1 | 20% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.25 |
| Highest Target | 5.00 |
| Lowest Target | 1.50 |

## References

- [Company Overview](https://longbridge.com/en/quote/INTS.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/INTS.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/INTS.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.